Stockscreener 앱 받기
2.21
6.45%
0.134
전일 마감가:
$2.076
열려 있는:
$1.96
하루 거래량:
1.18M
Relative Volume:
1.22
시가총액:
$7.65M
수익:
-
순이익/손실:
$-27.39M
주가수익비율:
-1.3152
EPS:
-1.6803
순현금흐름:
$-2.09M
1주 성능:
-46.88%
1개월 성능:
-47.03%
6개월 성능:
-84.06%
1년 성능:
+0.00%
1일 변동 폭
$1.6547
$2.24
1주일 범위
$1.6547
$4.184
52주 변동 폭
$1.6547
$84.00
Aspire Biopharma Holdings Inc Stock (ASBP) Company Profile
명칭
Aspire Biopharma Holdings Inc
전화
561-704-8527
주소
23150 FASHION DRIVE, SUITE 232, ESTERO
ASBP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ASBP
Aspire Biopharma Holdings Inc
|
2.21 | 179.63K | 0 | -27.39M | -2.09M | -1.6803 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Aspire Biopharma Holdings Inc 주식(ASBP)의 최신 뉴스
Aspire Biopharma Announces Reverse Stock Split - The Des Moines Register
Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin - Ventura County Star
Aspire Biopharma Holdings sets share limit for stock incentive plan and approves equity award agreements - Investing.com Nigeria
Aspire Biopharma Adopts Equity Plan Limits and Award Agreements - TipRanks
Aspire Biopharma announces 1-for-40 reverse stock split By Investing.com - Investing.com Nigeria
Aspire Biopharma announces 1-for-40 reverse stock split - Investing.com
Tiny drug developer shrinks share count 40-to-1 to keep Nasdaq listing - Stock Titan
Aspire Biopharma names new executive chair - MSN
Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA) - Panama City News Herald
Aspire Biopharma director Surendra Ajjarapu resigns from board By Investing.com - Investing.com Canada
Aspire Biopharma Announces Resignation of Board Director - TipRanks
Aspire Biopharma director Surendra Ajjarapu resigns from board - Investing.com
Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member - Pocono Record
Aspire Biopharma Approves Key Proposals at Special Meeting - MSN
Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack) - The Patriot Ledger
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
ASBP Stock Soars 32% After Favorable Feedback From FDA For Its Aspirin – Retail Expects Licensing Negotiations Soon - Stocktwits
FDA feedback clears path for Aspire Biopharma’s heart attack drug By Investing.com - Investing.com Nigeria
Aspire Biopharma Holdings, Inc.Common Stock (NQ: ASBP - FinancialContent
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Rockford Register Star: Local News, Politics & Sports in Rockford, IL - FinancialContent
Aspire Biopharma stock soars after FDA meeting clears path for heart attack drug - Investing.com Nigeria
Aspire Biopharma stock soars after FDA meeting clears path for heart attack drug By Investing.com - Investing.com South Africa
FDA feedback clears path for Aspire Biopharma’s heart attack drug - Investing.com India
FDA backs trial of faster-acting aspirin powder for heart attacks - Stock Titan
Aspire Biopharma Provides Q3 2025 Business Update - Oak Ridger
Aspire Biopharma (ASBP) Competitors and Alternatives 2026 - MarketBeat
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Aspire Biopharma Restructures Debt via Equity Exchange Agreements - TipRanks
Aspire Biopharma Holdings Signs Debt-for-Equity Exchange Agreements With Certain Debt Holders - TradingView — Track All Markets
Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements - Asbury Park Press
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Aspire Biopharma Holdings, Inc. Announces CEO Transition - aberdeennews.com
Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation - Pensacola News Journal
Aspire Biopharma Holdings, Inc. Warrant 2025-18.02.30 on Aspire Bio Hldgs Revenue Breakdown – NASDAQ:ASBPW - TradingView — Track All Markets
Aspire Biopharma Holdings, Inc. Warrant 2025-18.02.30 on Aspire Bio Hldgs - TradingView — Track All Markets
Aspire Biopharma Holdings Inc (ASBP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):